Results 81 to 90 of about 999,769 (295)

Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial

Trials, 2022
Background and rationale Idiopathic pulmonary fibrosis is a critical disease with a poor prognosis. Although different studies have been conducted for the treatment of idiopathic pulmonary fibrosis, limited treatments are available.
Shu-guang Yang, Xue-qing Yu, Jian-sheng Li, Yang Xie, Wei Zhang, Chengjun Ban, Jihong Feng, Lei Wu, Xuechao Lu, Limin Zhao, Yong Meng, Miao Zhou, Yong He, Weixian Luo   +13 more
doaj   +1 more source

Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis

European Respiratory Journal, 2019
A comprehensive understanding of the changes in gene expression in cell types involved in idiopathic pulmonary fibrosis (IPF) will shed light on the mechanisms underlying the loss of alveolar epithelial cells and development of honeycomb cysts and ...
C. Morse, T. Tabib, J. Sembrat, Kristina L. Buschur, H. T. Bittar, E. Valenzi, Yale Jiang, D. Kass, K. Gibson, Wei Chen, A. Mora, P. Benos, M. Rojas, R. Lafyatis   +13 more
semanticscholar   +1 more source

Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis [PDF]

, 2021
Rationale: There is an urgent need for simple, cost-effective prognostic biomarkers for idiopathic pulmonary fibrosis (IPF); biomarkers that show potential include monocyte count.
Lee, Joyce S, Molyneaux, Philip L, Kreuter, Michael, Tzouvelekis, Argyrios, Maher, Toby M, Atwood, Mark, Kirchgaessler, Klaus-Uwe, Oldham, Justin M, Weycker, Derek   +8 more
core   +1 more source

Therapy for Myhre Syndrome: Goals, Misconceptions, and Current Agents

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Myhre Syndrome (MYHRS, MIM #139210) is a rare, multisystem connective tissue disorder caused by recurrent heterozygous gain‐of‐function pathogenic variants in the SMAD4 gene, a key player in TGF‐β signaling and a regulator of extracellular matrix homeostasis.
Alessandro De Falco, Alfonso Manuel D'Alessio, Nicola Brunetti‐Pierri   +2 more
wiley   +1 more source

Identifying TNFSF4low-MSCs superiorly treating idiopathic pulmonary fibrosis through Tregs differentiation modulation

Stem Cell Research & Therapy
Background Idiopathic pulmonary fibrosis is a progressive lung disorder, presenting clinically with symptoms such as shortness of breath and hypoxemia. Despite its severe prognosis and limited treatment options, the pathogenesis of idiopathic pulmonary ...
Yuanyuan Xie, Qing Yi, Congwang Xu, Yaping Wang, Yue Jiang, Yirui Feng, Liudi Wang, Hui Yang, Yingwei Zhang, Bin Wang   +9 more
doaj   +1 more source

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

American Journal of Respiratory and Critical Care Medicine, 2016
Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically significant, respiratory deterioration of unidentifiable cause.
Harold R. Collard, C. Ryerson, T. Corte, Gisli Jenkins, Y. Kondoh, David J. Lederer, Joyce S. Lee, T. Maher, A. Wells, Katerina M. Antoniou, J. Behr, Kevin K. Brown, V. Cottin, Kevin R. Flaherty, Junya Fukuoka, D. Hansell, T. Johkoh, N. Kaminski, D. S. Kim, M. Kolb, D. Lynch, Jeffrey L. Myers, G. Raghu, L. Richeldi, Hiroyuki Taniguchi, Fernando J. Martinez   +25 more
semanticscholar   +1 more source

Idiopathic Pulmonary Fibrosis: Treatment and Prognosis

, 2015
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a prognosis that can be worse than for many cancers. The initial stages of the condition were thought to mainly involve chronic inflammation; therefore, corticosteroids and ...
Tetsu Kobayashi, Hajime Fujimoto, Arata Azuma   +2 more
core   +1 more source

Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis [PDF]

, 2012
Idiopathic pulmonary fibrosis (IPF) is a fatal disease that is unresponsive to current therapies and characterized by excessive collagen deposition and subsequent fibrosis.
Bozinovski, S, O'Donoghue, R.J.J., Prêle, C.M., Ernst, M.R., Anderson, GP, Vlahos, R., Knight, DA, McKenzie, B.S., Wang, B, Jarnicki, AG, Prêle, CM, Laurent, GJ, McAnulty, R.J., Thiem, S, Lau, HL, Vlahos, R, Zhu, H.J., Richards, CD, Mutsaers, SE, Ernst, MR, Stumbles, P.A., Laurent, G.J., Knight, D.A., Thiem, S., Jarnicki, A.G., Lau, H.L., O'Donoghue, RJJ, McAnulty, RJ, Stumbles, P, Richards, C.D., Anderson, G.P., McKenzie, BS, Rose-John, S, Mutsaers, S.E., Zhu, HJ, Wang, B., Jones, J., Rose-John, S., Jones, J, Bozinovski, S.   +39 more
core   +1 more source

Review of the Molecular and Developmental Basis of Myhre Syndrome, Bench Research

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Myhre syndrome (MS) is a connective‐tissue disorder within the acromelic dysplasia spectrum. It is characterized by congenital craniofacial, skeletal, cutaneous anomalies, respiratory, cardiovascular along with intellectual disability, deafness, and progressive fibrosis.
Camille Viaut, Valerie Cormier‐Daire
wiley   +1 more source

Normal Expiratory Flow Rate and Lung Volumes in Patients with Combined Emphysema and Interstitial Lung Disease: A Case Series and Literature Review

Canadian Respiratory Journal, 2011
Pulmonary function tests in patients with idiopathic pulmonary fibrosis characteristically show a restrictive pattern including small lung volumes and increased expiratory flow rates resulting from a reduction in pulmonary compliance due to diffuse ...
Karen L Heathcote, Donald W Cockcroft, Derek A Fladeland, Mark E Fenton   +3 more
doaj   +1 more source